Details of the Drug
General Information of Drug (ID: DMKT2MB)
Drug Name |
1-(4-nitrobenzyl)-1H-imidazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(4-Nitrobenzyl)-1H-imidazole; 18994-90-6; 1-(4-Nitrobenzyl)imidazole; 1-[(4-nitrophenyl)methyl]imidazole; Imidazole, 1-(4-nitrobenzyl)-; CHEMBL13784; 1H-Imidazole, 1-[(4-nitrophenyl)methyl]-; FLYGQJXMRPZYHQ-UHFFFAOYSA-N; 1-(4-Nitro-benzyl)-1H-imidazole; [(4-nitrophenyl)methyl]imidazole; AC1LBNLW; AC1Q1ZC3; ACMC-1C81T; SCHEMBL78081; CTK4E0266; DTXSID10342908; MolPort-001-494-965; KS-000024IG; ZINC1027711; ALBB-024046; CN-460; ANW-23472; STK149522; SBB093104; BDBM50188093; 1-(4-Nitrobenzyl)-1H-imidazole #; AKOS003266265; VI10027
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 203.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||